Proactiveinvestors United Kingdom Scancell Holdings PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Scancell Holdings PLC RSS feed en Thu, 18 Jul 2019 23:14:29 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials ]]> https://www.proactiveinvestors.co.uk/companies/news/223113/scancell-on-verge-of-recruiting-patients-with-advanced-melanoma-for-uk-clinical-trials-223113.html Scancell Holdings PLC (LON:SCLP) shares advanced on Monday after rthe firm provided an upbeat half-year update on progress for its various clinical studies.

The company will begin recruiting patients with advanced melanoma for UK Phase 2 clinical trials of its SCIB1 novel cancer immunotherapy in the coming weeks, following regulatory approval in April.

WATCH: Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

In order to begin the study in the US there are talks ongoing with the regulator about administering the drugs using the TriGrid electroporation delivery system.

Saying that he looked forward to updating the market on the US arm of this trial and patient recruitment in due course, Scancell's chief executive Dr Cliff Holloway summed up the six-month period as “busy and productive”.

Progress towards initiating a Phase 1/2 clinical trial for Modi-1, the first cancer treatment from the company’s Moditope platform, has seen formulation work “well underway” to produce the final product for clinical testing and initiation of the preclinical toxicity testing programme.

On the SCIB2 ImmunoBody vaccine, there was no fresh news since May’s milestone joint update with Cancer Research UK that showed the potency of immune responses and prolonged survival in pre-clinical trials ahead of moving into the clinic with patients suffering from solid tumours.

Holloway also hailed the establishment of a clinical advisory board and the £3.9mln new investment from Vulpes Life Sciences in June, saying the investment “not only strengthens our cash position, but provides a ringing endorsement of Scancell's future potential”, as well as adding insight to the board.

In afternoon trading, shares in Scancell were 5.9% higher at 7.15p.

 -- Adds share price -- 

]]>
Mon, 01 Jul 2019 08:24:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223113/scancell-on-verge-of-recruiting-patients-with-advanced-melanoma-for-uk-clinical-trials-223113.html
<![CDATA[RNS press release - H1 2019 Business Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190701070010_14130330/ Mon, 01 Jul 2019 07:00:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190701070010_14130330/ <![CDATA[Media files - Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13831/vulpes-life-sciences-fund-s-martin-diggle-discusses-scancell-investment-13831.html Fri, 21 Jun 2019 10:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13831/vulpes-life-sciences-fund-s-martin-diggle-discusses-scancell-investment-13831.html <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190618091607_14114844/ Tue, 18 Jun 2019 09:16:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190618091607_14114844/ <![CDATA[RNS press release - Board Appointment ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190618070013_14114140/ Tue, 18 Jun 2019 07:00:13 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190618070013_14114140/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190617104504_14113289/ Mon, 17 Jun 2019 10:45:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190617104504_14113289/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190614164101_14112168/ Fri, 14 Jun 2019 16:41:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190614164101_14112168/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190614163536_14112157/ Fri, 14 Jun 2019 16:35:36 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190614163536_14112157/ <![CDATA[Media files - Scancell welcomes strategic new investor Vulpes Life Sciences Fund ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13724/scancell-welcomes-strategic-new-investor-vulpes-life-sciences-fund-13724.html Thu, 13 Jun 2019 11:53:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13724/scancell-welcomes-strategic-new-investor-vulpes-life-sciences-fund-13724.html <![CDATA[News - Scancell raises £3.9mln to advance immunotherapy product pipeline ]]> https://www.proactiveinvestors.co.uk/companies/news/222043/scancell-raises-39mln-to-advance-immunotherapy-product-pipeline-222043.html Scancell Holdings PLC (LON:SCLP), the cancer immunotherapy specialist, has raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company when the shares are issued next Monday.

WATCH: Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Along with the stake in the company, Martin Diggle, co-founder of the fund’s owner, Vulpes Investment Management, and an experienced investor in the life science sector, has been proposed as a non-executive director.

Diggle, having conducted scientific and commercial due diligence on Scancell for some time, said Vulpes felt it was an “exciting time” in the evolution of the company, where he believed its “unique and innovative approach to fighting cancer is compelling and under-appreciated”.

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Scancell chairman John Chiplin said: “This new investment capital increases funds available to advance our product pipeline and in particular, the transition of our lead Moditope platform asset Modi-1 into the clinic.

Modi-1, part of a new class of selective immunotherapy agents that stimulate the production of killer T cells that overcome the immune suppression induced by tumours, is expected to enter the clinic in the first quarter of 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.

Scancell shares were up almost 8% to 5.76p in early trading on Thursday.

]]>
Thu, 13 Jun 2019 08:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222043/scancell-raises-39mln-to-advance-immunotherapy-product-pipeline-222043.html
<![CDATA[RNS press release - Share Subscription and Issue of Equity to Vulpes ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190613070007_14109010/ Thu, 13 Jun 2019 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190613070007_14109010/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190529110557_14090833/ Wed, 29 May 2019 11:05:57 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190529110557_14090833/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190529110035_14090822/ Wed, 29 May 2019 11:00:35 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190529110035_14090822/ <![CDATA[News - Scancell exploring new frontiers in cancer research ]]> https://www.proactiveinvestors.co.uk/companies/news/220600/scancell-exploring-new-frontiers-in-cancer-research-220600.html AIM-listed Scancell Holdings PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing promise – they are the ImmunoBody and Moditope platforms. The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2. It is also developing MODI-1 and MODI-2 from the Moditope platform.

Recent time-line 

In April the firm said it was to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug within weeks, after receiving approval from regulators. The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s blockbuster checkpoint inhibitor, Keytruda.

The UK arm of the trial is scheduled to get underway before the end of June, and the Scancell team are working to secure approvals from US regulators so trials can also start across the pond. Last October, the US Food and Drug Administration (FDA) requested some more information around TriGrid – a delivery system developed by a third party – before granting SCIB1 investigational new drug status.

In May, Sancell and cancer Cancer Research UK (CRUK) announced further progress with Scancell's SCIB2 cancer immunotherapy vaccine. Pre-clinical studies have demonstrated that the administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.

Inflexion points

The company expects to generate meaningful clinical data in the next two years from all four of its drug candidates (see below).

 

In recent updates investors have been told CRUK is planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

And a planned phase I/II clinical study is of MODI-1 is expected to begin in the second half.

]]>
Mon, 20 May 2019 11:51:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220600/scancell-exploring-new-frontiers-in-cancer-research-220600.html
<![CDATA[News - Scancell surges after announcing milestone in development of its solid tumours treatment ]]> https://www.proactiveinvestors.co.uk/companies/news/220580/scancell-surges-after-announcing-milestone-in-development-of-its-solid-tumours-treatment-220580.html Scancell Holdings PLC (LON:SCLP) and the cancer charity Cancer Research UK have announced further progress with Scancell's SCIB2 cancer immunotherapy vaccine.

Pre-clinical studies have demonstrated that the administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.

READ Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The nanoparticle technology uses known lipid (soluble biomolecules) carriers that are optimised to deliver SCIB2 DNA to immune cells. The liposomal nanoparticles protect the DNA from degradation and facilitate efficient uptake, expression and T-cell activation against cancer cells, said Scancell.

The nanoparticle delivery system provides an alternative approach to electroporation - an electrical technique that involves the application of high-voltage electric pulses in short bursts – that has been used to deliver other ImmunoBody agents to patients.

Cancer Research UK is now planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

Dr Cliff Holloway, the chief executive officer of Scancell, said the latest milestone “moves us one step closer to entering the clinic”.

“This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporation. We believe SCIB2 has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours including NSCLC, the most frequent cause of cancer death globally,” Holloway added.

Dr Nigel Blackburn, Cancer Research UK's director of drug development, said the vaccine could bring about urgently needed improvements for some cancer treatments.

“Our collaboration with Scancell, combining extensive expertise and experience in drug development, will help bring this treatment to the patients that need it sooner,” Blackburn declared.

Shares in Scancell were up 12% at 4.75p in early deals.

]]>
Mon, 20 May 2019 08:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220580/scancell-surges-after-announcing-milestone-in-development-of-its-solid-tumours-treatment-220580.html
<![CDATA[RNS press release - Scancell and CRUK provide an update on SCIB2 ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190520070026_14079388/ Mon, 20 May 2019 07:00:26 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190520070026_14079388/ <![CDATA[News - Scancell adds six ‘world-leading’ cancer specialists to advisory board ahead of Modi-1 trial ]]> https://www.proactiveinvestors.co.uk/companies/news/220030/scancell-adds-six-world-leading-cancer-specialists-to-advisory-board-ahead-of-modi-1-trial-220030.html Scancell Holdings PLC (LON:SCLP) has added six “world-leading” cancer specialists to its clinical advisory board as the drug developer prepares for its Modi-1 cancer treatment to enter the clinic early next year.

AIM-quoted Scancell’s clinical advisory boards now boasts some of the brightest and most respected cancer researchers that the UK has to offer.

READ: Scancell to begin UK arm of skin cancer trial within weeks

The University of Sheffield’s emeritus professor of medical oncology, Robert Coleman, is joined by Christian Ottensmeier, a professor of experimental cancer medicine treatment at the University of Southampton.

Imperial College London professor of oncology, Iain McNeish, Mount Vernon cancer centre’s lead breast cancer clinician David Miles, Nottingham University Hospital’s Stephen Chan and Poulam Patel, professor of clinical oncology at the University of Nottingham, have also joined the board.

“We are delighted to welcome all six experienced clinicians to our clinical advisory board and the creation of this Board is part of our wider strategy to fully develop and deliver the full potential of the Moditope platform across multiple tumour types,” said Scancell chief executive Cliff Holloway.

“The initial focus of the board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications, including ovarian cancer, head and neck cancer, and triple negative breast cancer.”

‘Significant progress’ made

Modi-1 is Scancell’s first drug using its Moditope technology. It acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells which would otherwise be hidden from the immune system. 

A phase I/II study is set to begin in the first quarter of 2020, which will see Modi-1 trialled in patients with various types of cancer, including head and neck, breast and ovarian.

Scancell confirmed on Friday that preparation for the trial is well underway. A Scottish firm has now been chosen to manufacture and package the final Modi-1 product, while a preclinical toxicity testing programme got underway last month and is expected to be wrapped up later this year.

Holloway added: “Significant progress has been made towards completing the GMP manufacture of the Modi-1 product and the preclinical testing required prior to the anticipated start of the trial early in 2020.”

]]>
Fri, 10 May 2019 07:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220030/scancell-adds-six-world-leading-cancer-specialists-to-advisory-board-ahead-of-modi-1-trial-220030.html
<![CDATA[RNS press release - Clinical Advisory Board and Update on Modi-1 ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190510070006_14069063/ Fri, 10 May 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190510070006_14069063/ <![CDATA[Media files - Scancell to begin dosing in UK phase II trial of flagship skin cancer drug ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13102/scancell-to-begin-dosing-in-uk-phase-ii-trial-of-flagship-skin-cancer-drug-13102.html Thu, 25 Apr 2019 12:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13102/scancell-to-begin-dosing-in-uk-phase-ii-trial-of-flagship-skin-cancer-drug-13102.html <![CDATA[News - Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks ]]> https://www.proactiveinvestors.co.uk/companies/news/219074/scancell-higher-as-it-is-to-begin-uk-arm-of-phase-ii-skin-cancer-trial-within-weeks-219074.html Scancell Holdings PLC (LON:SCLP) shares rose on Thursday as the firm said it is to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug within weeks, after receiving approval from regulators.

The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s blockbuster checkpoint inhibitor Keytruda.

READ: Scancell wins Japanese patent protection

Earlier research carried out by Scancell suggested that combining SCIB1 with a checkpoint inhibitor could have a bigger impact than if it were administered on its own.

“This is a major milestone in the clinical advancement of our SCIB1 programme and we look forward to initiating this important phase II study,” said chief executive Cliff Holloway.

“Our preclinical research has indicated that SCIB1 administration with an immune checkpoint inhibitor has the potential to offer even greater efficacy than when either agent is given alone, and this new study is designed to evaluate the safety and efficacy of this approach in patients with inoperable disease.”

‘Compelling’ phase I/II performance

Scancell’s immunotherapy, which targets and stimulate existing cells that make up the body’s defence mechanisms, has already shown itself to be safe and well-tolerated in a prior phase I/II study.

In that same trial, SCIB1 also demonstrated its potential to improve survival rates, with 14 of 16 patients with resected skin cancer (i.e. some or all the tumour has been surgically removed in the past) remaining alive for more than five years after diagnosis.

Typically, only around 20% of people with advanced melanoma – stage III/IV – make it that far.

Discussions ongoing with US regulators

The UK arm of the trial is scheduled to get underway before the end of June, and CEO Holloway and his team are working to secure approvals from US regulators so trials can also start across the pond.

In October, the US Food and Drug Administration (FDA) requested some more information around TriGrid – a delivery system developed by a third party – before granting SCIB1 investigational new drug status.

Holloway said: “Discussions with the FDA are ongoing and we continue to work with Ichor towards IND approval to open our US study centres.”

In afternoon trading, shares in Scancell were 2,6% higher at  5.30p.

 -- Adds share price --

]]>
Thu, 25 Apr 2019 07:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219074/scancell-higher-as-it-is-to-begin-uk-arm-of-phase-ii-skin-cancer-trial-within-weeks-219074.html
<![CDATA[RNS press release - UK approval to start SCIB1 Phase 2 trial ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190425070004_14050956/ Thu, 25 Apr 2019 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190425070004_14050956/ <![CDATA[News - Scancell Holdings wins Japanese patent protection ]]> https://www.proactiveinvestors.co.uk/companies/news/218116/scancell-holdings-wins-japanese-patent-protection-218116.html Scancell Holdings PLC (LON:SCLP) shares rose on Monday after the group revealed it has won Japanese patent protection for its Moditope immunotherapy platform.

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia, and acceptance for a grant in China.

READ: Scancell strengthens IP with two “important” patent grants in US and Europe

“We look forward to continuing to advance Modi-1, the first product from this platform, towards clinical development," said chief executive, Dr Cliff Holloway.

Moditope is one of two platforms the company has developed – the other is ImmunoBody, which has spawned SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

The UK group is planning to use SCIB1 in harness with Merck’s Keytruda checkpoint inhibitor to treat patients with advanced melanoma.

In mid-morning trading, shares in Scancell were up 2% at 5.2p.

 -- Adds share price --

]]>
Mon, 08 Apr 2019 07:37:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218116/scancell-holdings-wins-japanese-patent-protection-218116.html
<![CDATA[RNS press release - Japan patent for Moditope immunotherapy platform ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190408070008_14031710/ Mon, 08 Apr 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190408070008_14031710/ <![CDATA[RNS press release - Professor Lindy Durrant receives Waldenström award ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190321070019_14010019/ Thu, 21 Mar 2019 07:00:19 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190321070019_14010019/ <![CDATA[News - Scancell strengthens IP with two “important” patent grants in US and Europe ]]> https://www.proactiveinvestors.co.uk/companies/news/216814/scancell-strengthens-ip-with-two-important-patent-grants-in-us-and-europe-216814.html Scancell Holdings PLC (LON:SCLP) has strengthened its intellectual property (IP) after it was granted two “important” patents in the US and Europe.

The US patent covers Modi-1 – the first clinical candidate from Scancell’s Moditope immunotherapy platform.

It claims methods of stimulating an immune response to a tumour and methods of treating cancer using peptides of Modi-1.

READ: Scancell lauds another six months of progress

Similar protection has already been granted in Europe, South Africa, and Australia, as well as acceptance for grant in China.

As for the European patent announced today, that relates to FG88, a monoclonal antibody directed to tumour associated glycans, which Scancell said further strengthens the commercial positioning of its monoclonal antibody development programme.

“We are pleased to have been granted these two important patents for our immunotherapy platforms in the United States and Europe,” said chief executive Cliff Holloway.

“This Moditope patent provides protection for Modi-1 in the US and further endorses the novelty of Scancell's work in identifying a new class of cancer vaccine.”

He added: “Through the continued expansion of our intellectual property portfolio in the US and Europe, we believe we are well positioned to advance our pipeline of novel immunotherapies.”

]]>
Wed, 20 Mar 2019 07:55:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216814/scancell-strengthens-ip-with-two-important-patent-grants-in-us-and-europe-216814.html
<![CDATA[RNS press release - Scancell strengthens IP portfolio ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190320070006_14008289/ Wed, 20 Mar 2019 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190320070006_14008289/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190305182700_13991309/ Tue, 05 Mar 2019 18:27:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190305182700_13991309/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190304164034_13989599/ Mon, 04 Mar 2019 16:40:34 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190304164034_13989599/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190304163535_13989589/ Mon, 04 Mar 2019 16:35:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190304163535_13989589/ <![CDATA[RNS press release - Change of Auditor ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190221070020_13976493/ Thu, 21 Feb 2019 07:00:20 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190221070020_13976493/ <![CDATA[News - Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise ]]> https://www.proactiveinvestors.co.uk/companies/news/214474/scancell-in-vanguard-of-immuno-oncology-advances-with-two-technologies-that-show-early-promise-214474.html  

What Scancell does:

AIM-listed Scancell PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise – they are the ImmunoBody and Moditope platforms.

The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

The UK group is planning to use SCIB1 in harness with Merck’s Keytruda checkpoint inhibitor to treat patients with advanced melanoma.

How is it doing it:

Scancell’s interim results in January showed that the company has the cash to advance its pipeline of immunotherapy products.

The group ended the six-month period to the end of October with a positive cash balance of £7.6mln, down from £10.3mln six months earlier.

The pre-revenue company saw its loss before tax widen to £3.67mln from £2.39mln the year before.

Scancell's focus for the immediate future is to initiate the planned Phase 2 clinical study for its lead ImmunoBody, SCIB1, and to advance its lead Moditope vaccine, Modi-1, towards the clinic.

Back in October 2018, Scancell said it is working closely with the US drugs regulator to address questions raised ahead of the launch of a Phase II clinical study of SCIB1 in combination with Keytruda.

Ahead of the granting investigational new drug status, America’s Food & Drug Administration requested some additional information, with the queries focused on a technology called TriGrid, a delivery system developed by Ichor Medical Systems that is also part of the combination therapy.

Subject to regulatory sign-off, Scancell said it expects patient enrolment for the trial to begin in the first half of this year.

READ: Scancell lauds another six months of progress

In the same month, Scancell reported that pre-clinical data for its Modi-2 vaccine has the potential to treat different types of cancer to its forerunner, Modi-1.

Modi-2 is the second vaccine developed from Scancell’s Moditope platform, with Modi-1, the lead vaccine due to enter the clinic in 2019.

The two drugs work in slightly different ways, although both stimulate the production of CD4 T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Modi-1 will be tested as a treatment for breast and ovarian cancers, as well as sarcoma (tumours found in fat, muscle, bone and tendons) when its clinical trial begins next year.

But Scancell thinks Modi-2 has the potential to address different cancer indications to Modi-1, including tumours which work particularly hard to suppress the immune system.

The company received “significant scientific endorsement” of its technology in January 2019 after it and a group of collaborators were shortlisted for a major award.

Scancell teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

As it gears up for its next phase of development, Scancell made two experienced hires in January 2019.

T-cell cloning specialist Dr Samantha Paston was appointed the company’s new head of research, while Dr Adrian Parry will take charge of manufacturing.

Paston arrived in mid-January from Oxford-based biotech unicorn Immunocore, where she made “significant contributions” to the company’s current oncology pipeline.

Before joining Immunocore, she held roles at Medigene, Avidex, NIBSC and GlaxoSmithKline. She gained her PhD at University College London.

Parry joined Scancell on February 1 from Mereo BioPharma, where he was head of small molecule chemistry, manufacturing and controls.

What the boss says - Cliff Holloway

“The shortlisting of our proposal represents a significant scientific endorsement of Scancell's technology and the team remains committed to meeting the challenges of improving cancer vaccines for all patients.”

Blue Sky:

At the turn of last year, Scancell reported “compelling” results from the Phase I/II melanoma trial of SCIB-1, and now it is waiting to kick off the Phase II clinical study of SCIB1 in combination with Keytruda later this year.

In December 2017, Cancer Research UK agreed to fund and sponsor a Phase I/II lung cancer clinical study of Scancell’s SCIB-2 vaccine, also in combination with a checkpoint inhibitor.

Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.

That is more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.

In May 2018, investors got behind the business, backing a placing and subscription and open offer of new shares that brought in £8.7mln before expenses.

Those shares were sold at 12p each, but since then, the stock has drifted steadily back, currently trading at 6.30p, valuing Scancell at £25.79mln.

News on the start of the Phase II clinical study of SCIB1 in combination with Keytruda could see it return to the £50mln valuation of the May 2018 placing price.

]]>
Tue, 12 Feb 2019 15:07:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214474/scancell-in-vanguard-of-immuno-oncology-advances-with-two-technologies-that-show-early-promise-214474.html
<![CDATA[News - Scancell lauds another six months of progress ]]> https://www.proactiveinvestors.co.uk/companies/news/213702/scancell-lauds-another-six-months-of-progress-213702.html Scancell Holdings PLC (LON:SCLP) said in its interim results that it has the cash to advance its pipeline of immunotherapy products.

The group ended the six month period to the end of October with a positive cash balance of £7.6mln, down from £10.3mln a year earlier.

READ: Scancell hires two industry veterans as it gears up for the next development phase

The pre-revenue company saw its loss before tax widen to £3.67mln from £2.39mln the year before.

Scancell's focus for the immediate future is to initiate the planned Phase 2 clinical study for its lead ImmunoBody, SCIB1, and to advance its lead Moditope vaccine, Modi-1, towards the clinic.

READ: Scancell licenses TriGrid electroporation device from Ichor Medical Systems

A positive outcome from both or either of these studies should represent significant value to shareholders, said John Chiplin, the company’s chairman.

READ: Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy 

"We are pleased to report another six months of progress at Scancell,” said Cliff Holloway, the chief executive officer of Scancell.

“We are working closely with Ichor and the FDA to provide the additional information requested for the initiation of our Phase 2 checkpoint inhibitor combination study of SCIB1 in patients with advanced melanoma,” he added.

  ]]>
Thu, 31 Jan 2019 08:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213702/scancell-lauds-another-six-months-of-progress-213702.html
<![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190131070008_13952719/ Thu, 31 Jan 2019 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190131070008_13952719/ <![CDATA[Media files - Award shortlist 'a significant scientific endorsement' of Scancell's technology ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11959/award-shortlist--a-significant-scientific-endorsement--of-scancell-s-technology-11959.html Wed, 23 Jan 2019 12:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11959/award-shortlist--a-significant-scientific-endorsement--of-scancell-s-technology-11959.html <![CDATA[News - Scancell receives “significant scientific endorsement” for technology ]]> https://www.proactiveinvestors.co.uk/companies/news/213126/scancell-receives-significant-scientific-endorsement-for-technology-213126.html Scancell Holdings Plc (LON:SCLP) said it had received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

READ: Scancell makes two experience hires as it gears up for the next development phase

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

While ultimately unsuccessful in landing the top prize, the AIM-listed company was “delighted” its submission made it to the final stages.

"We would like to congratulate the winners of Cancer Research UK's Grand Challenge, and to thank Cancer Research UK for putting the challenge forward to some of the best researchers in the world,” said Professor Lindy Durrant, Scancell’s chief scientific officer.

“The shortlisting of our proposal represents a significant scientific endorsement of Scancell's technology and the team remains committed to meeting the challenges of improving cancer vaccines for all patients.”

The drug developer, which is at the cutting edge of immunotherapy where the body’s own defences are used to fight disease, is currently gearing up to take its lead compound, SCIB1, into phase II clinical trials.

]]>
Wed, 23 Jan 2019 07:27:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213126/scancell-receives-significant-scientific-endorsement-for-technology-213126.html
<![CDATA[RNS press release - Update on Cancer Research UK's Grand Challenge ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190123070005_13943393/ Wed, 23 Jan 2019 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190123070005_13943393/ <![CDATA[News - Scancell hires two industry veterans as it gears up for the next development phase ]]> https://www.proactiveinvestors.co.uk/companies/news/212933/scancell-hires-two-industry-veterans-as-it-gears-up-for-the-next-development-phase-212933.html Scancell Holdings PLC (LON:SCLP) has made two experienced hires as it gears up for its next phase of development.

T-cell cloning specialist Dr Samantha Paston is the company’s new head of research, while Dr Adrian Parry will take charge of manufacturing.

Paston arrived in mid-January from Oxford-based biotech unicorn Immunocore, where she made “significant contributions” to the company’s current oncology pipeline.

Before joining Immunocore, she held roles at Medigene, Avidex, NIBSC and GlaxoSmithKline. She gained her PhD at University College London.

Parry joins Scancell on February 1 from Mereo BioPharma, where he was head of small molecule chemistry, manufacturing and controls).

He has over two decades’ experience delivering “multiple, complex” drug products.

“We are delighted to welcome both Samantha and Adrian to Scancell,” said chief executive Cliff Holloway.

“Samantha’s experience in T-cell cloning and working with biological molecules, from drug discovery through to early development, will be invaluable as we continue to progress our pipeline of cancer immunotherapies.

“Likewise, Adrian’s 20 years of CMC and GMP development expertise will be key for our manufacturing capabilities moving forward.”

AIM-listed Scancell is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise – they are the ImmunoBody and Moditope platforms.

The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

The UK group is planning to use SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma.

]]>
Mon, 21 Jan 2019 07:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212933/scancell-hires-two-industry-veterans-as-it-gears-up-for-the-next-development-phase-212933.html
<![CDATA[RNS press release - Appoints Heads of Research and Manufacturing ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190121070008_13940473/ Mon, 21 Jan 2019 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20190121070008_13940473/ <![CDATA[RNS press release - Scancell to Present at Two Conferences ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181112070006_13862573/ Mon, 12 Nov 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181112070006_13862573/ <![CDATA[RNS press release - Scancell to present at Proactive Investors Forum ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181101070007_13850524/ Thu, 01 Nov 2018 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181101070007_13850524/ <![CDATA[RNS press release - Results of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181030171837_13848293/ Tue, 30 Oct 2018 17:18:37 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181030171837_13848293/ <![CDATA[News - Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies ]]> https://www.proactiveinvestors.co.uk/companies/news/208085/scancells-modi-2-anti-cancer-vaccine-shows-potential-in-pre-clinical-studies-208085.html Pre-clinical data has shown that Scancell Holdings PLC’s (LON:SCLP) Modi-2 vaccine has the potential to treat different types of cancer to its forerunner, Modi-1.

Modi-2 is the second vaccine developed from Scancell’s Moditope platform after Modi-1, the lead Moditope vaccine which is due to enter the clinic in 2019.

IN-DEPTH: Scancell part of the new cancer revolution

The two drugs work in slightly different ways, although both stimulate the production of CD4 T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Modi-1 will be tested as a treatment for breast and ovarian cancers, as well as sarcoma (tumours found in fat, muscle, bone and tendons) when its clinical trial begins next year.

But Scancell thinks Modi-2 has the potential to address different cancer indications to Modi-1, including tumours which work particularly hard to suppress the immune system.

“We are pleased to be able to provide an update on the progress of our second Moditope vaccine, Modi-2,” said chief scientific officer Lindy Durrant.

“The data clearly demonstrates the potential of homocitrullinated (Modi-2), as well as citrullinated (Modi-1), tumour-associated peptide epitopes to be developed for the treatment of solid cancers.”

Scancell shares rose 0.8% to 7.8p in mid-afternoon trade.

-- Updates for share price --

]]>
Tue, 30 Oct 2018 07:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208085/scancells-modi-2-anti-cancer-vaccine-shows-potential-in-pre-clinical-studies-208085.html
<![CDATA[RNS press release - Identification of 2nd Moditope Cancer Vaccine ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181030070008_13846732/ Tue, 30 Oct 2018 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181030070008_13846732/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181024090545_13840411/ Wed, 24 Oct 2018 09:05:45 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181024090545_13840411/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181024090016_13840410/ Wed, 24 Oct 2018 09:00:16 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181024090016_13840410/ <![CDATA[News - Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy ]]> https://www.proactiveinvestors.co.uk/companies/news/207727/scancell-says-it-is-working-closely-with-us-regulators-ahead-of-phase-ii-study-of-cancer-immunotherapy-207727.html Scancell Holdings Plc (LON:SCLP) said it is working closely with the US drugs regulator to address questions raised ahead of the launch of a phase II clinical study of its cancer immunotherapy.a

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma.

Ahead of granting investigational new drug status, America’s Food & Drug Administration has requested some additional information.

Focus on TriGrid

The queries are focused on a technology called TriGrid, a delivery system developed by Ichor Medical Systems that is also part of the combination therapy.

Chief executive Cliff Holloway said: "We are working closely with Ichor and the FDA to address the questions they have raised and we are confident we can respond to these in a timely manner. 

“We continue to advance the operational processes and procedures to ensure a rapid start to the study once approval is obtained."

Subject to regulatory sign-off, Scancell expects patient enrolment to begin in the first half of next year.

]]>
Wed, 24 Oct 2018 07:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207727/scancell-says-it-is-working-closely-with-us-regulators-ahead-of-phase-ii-study-of-cancer-immunotherapy-207727.html
<![CDATA[RNS press release - Update on SCIB1 Phase 2 Clinical Study ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181024070001_13839812/ Wed, 24 Oct 2018 07:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181024070001_13839812/ <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181005070004_13817512/ Fri, 05 Oct 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20181005070004_13817512/ <![CDATA[RNS press release - Final Results for the year ended 30 April 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20180925070006_13802801/ Tue, 25 Sep 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20180925070006_13802801/ <![CDATA[RNS press release - Notice of Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20180918070020_13794055/ Tue, 18 Sep 2018 07:00:20 +0100 https://www.proactiveinvestors.co.uk/companies/rns/3362/LSE20180918070020_13794055/